ACS Applied Energy Materials最新文献

Exploring prognostic factors for survival in patients with advanced pancreatic cancer undergoing PD-1 inhibitor immunotherapy. 探索接受 PD-1 抑制剂免疫疗法的晚期胰腺癌患者的生存预后因素。

IF 4.1 3区材料科学

ACS Applied Energy Materials Pub Date : 2024-12-31 Epub Date: 2024-07-23 DOI: 10.1080/21645515.2024.2376429

Yue Ma, Shiyun Chen, Guanghai Dai

{"title":"Exploring prognostic factors for survival in patients with advanced pancreatic cancer undergoing PD-1 inhibitor immunotherapy.","authors":"Yue Ma, Shiyun Chen, Guanghai Dai","doi":"10.1080/21645515.2024.2376429","DOIUrl":"10.1080/21645515.2024.2376429","url":null,"abstract":"Immunotherapy, led by programmed cell death protein-1 (PD-1) inhibitors, has emerged as a prominent antitumor therapy, yet prognostic challenges persist in pancreatic cancer (PC). This retrospective, single-center study evaluated prognostic factors in advanced PC patients treated with PD-1 inhibitors at the PLA General Hospital's Oncology Department from 2015-2022. With ethics approval by the Ethics Committee of the General Hospital of the People's Liberation Army (S2021-228-03), we analyzed 126 patients using Kaplan-Meier and Cox models. p < .05 was considered a statistically significant difference. Median overall survival (mOS) and progression-free survival (mPFS) were 12.1 and 4.6 months, respectively. Significant mOS predictors were surgery history (44.2 months vs. 10 months, *p = .022), absence of liver metastases (44.2 months vs. 6.4 months, *p = .034), and baseline CA19-9 ≤ 216.15 U/ml (18.5 months vs. 9.2 months, *p = .049). For mPFS, histologic differentiation (5.5 months vs. 3.2 months, *p = .022) and first-line PD-1 inhibitor use (5.1 months vs. 1.5 months, ***p = .001) were key. Subgroup analyses highlighted early progression in low histologic differentiation and earlier death without surgery. History of surgery, absence of liver metastases, baseline CA19-9 level, and histologic intermediate/high differentiation may predict PD-1 inhibitor efficacy in advanced PC, pending validation in prospective trials.","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"20 1","pages":"2376429"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141749416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaccine approaches to treat urothelial cancer. 治疗尿道癌的疫苗方法。

IF 4.1 3区材料科学

ACS Applied Energy Materials Pub Date : 2024-12-31 Epub Date: 2024-07-23 DOI: 10.1080/21645515.2024.2379086

Giulia Claire Giudice, Guru P Sonpavde

{"title":"Vaccine approaches to treat urothelial cancer.","authors":"Giulia Claire Giudice, Guru P Sonpavde","doi":"10.1080/21645515.2024.2379086","DOIUrl":"10.1080/21645515.2024.2379086","url":null,"abstract":"Bladder cancer (BC) accounts for about 4% of all malignancies. Non-muscle-invasive BC, 75% of cases, is treated with transurethral resection and adjuvant intravesical instillation, while muscle-invasive BC warrants cisplatin-based perioperative chemotherapy. Although immune-checkpoint inhibitors, antibody drug conjugates and targeted agents have provided dramatic advances, metastatic BC remains a generally incurable disease and clinical trials continue to vigorously evaluate novel molecules. Cancer vaccines aim at activating the patient's immune system against tumor cells. Several means of delivering neoantigens have been developed, including peptides, antigen-presenting cells, virus, or nucleic acids. Various improvements are constantly being explored, such as adjuvants use and combination strategies. Nucleic acids-based vaccines are increasingly gaining attention in recent years, with promising results in other malignancies. However, despite the recent advantages, numerous obstacles persist. This review is aimed at describing the different types of cancer vaccines, their evaluations in UC patients and the more recent innovations in this field.","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"20 1","pages":"2379086"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Seroprevalence of antibodies against varicella zoster virus across all age groups during the post-COVID-19 pandemic period in Chonburi Province, Thailand. 泰国春武里府各年龄组水痘带状疱疹病毒抗体的血清流行率（后 COVID-19 大流行时期）。

IF 4.1 3区材料科学

ACS Applied Energy Materials Pub Date : 2024-12-31 Epub Date: 2024-07-25 DOI: 10.1080/21645515.2024.2367283

Thanunrat Thongmee, Jira Chansaenroj, Sirapa Klinfueng, Ratchadawan Aeemjinda, Nasamon Wanlapakorn, Yong Poovorawan

{"title":"Seroprevalence of antibodies against varicella zoster virus across all age groups during the post-COVID-19 pandemic period in Chonburi Province, Thailand.","authors":"Thanunrat Thongmee, Jira Chansaenroj, Sirapa Klinfueng, Ratchadawan Aeemjinda, Nasamon Wanlapakorn, Yong Poovorawan","doi":"10.1080/21645515.2024.2367283","DOIUrl":"10.1080/21645515.2024.2367283","url":null,"abstract":"As of 2024, Thailand has not incorporated the varicella-zoster virus (VZV) vaccine into the Expanded Program on Immunization (EPI). This study aimed to evaluate VZV seroprevalence across all age groups in Chonburi Province, Thailand, during the post-COVID-19 era, and to support the development of a vaccination plan against VZV. A total of 950 participants were enrolled from October 2022 to January 2023. VZV antibody levels were measured using ELISA kits (EUROIMMUN, Lübeck, Germany), with seropositivity set at ≥110 IU/L. The overall VZV seropositivity rate was 64.8%, similar to rates in 1994 and 2014. However, seropositivity rates for the 5-9, 10-14, and 15-19 age groups were significantly higher in the 1994 study, and for the 10-14 and 15-19 age groups in the 2014 study, indicating a declining trend among young Thai individuals. The seropositivity rate increased with age, with a seroprevalence exceeding 80% in individuals aged 30 years and older. Our study found a significant association between the history of varicella and seropositivity. Thus, a positive history may indicate immunity. In conclusion, a significant portion of Thai adolescents are still vulnerable to varicella, highlighting the crucial role of vaccination in averting serious illness.","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"20 1","pages":"2367283"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11275523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France. 法国首批接受西帕维巴特作为 COVID-19 暴露前预防早期治疗的免疫力低下患者的特征。

IF 4.1 3区材料科学

ACS Applied Energy Materials Pub Date : 2024-12-31 Epub Date: 2024-08-14 DOI: 10.1080/21645515.2024.2387221

Paul Loubet, Benjamin Gaborit, Mathilde Salpin, Hèlene Gardeney, Ilies Benotmane, Thomas Systchenko

引用次数: 0

Response to comment on "A bibliometric analysis of vaccination against atherosclerosis". 对 "动脉粥样硬化疫苗接种的文献计量分析 "评论的回应。

IF 4.1 3区材料科学

ACS Applied Energy Materials Pub Date : 2024-12-31 Epub Date: 2024-08-14 DOI: 10.1080/21645515.2024.2377851

Bochao Jia, Rui Wei, Chenlu Yuan, Tao Cheng, Shuai Shi, Yuguang Chu, Yuanhui Hu

引用次数: 0

Correction. 更正。

IF 4.4 3区材料科学

ACS Applied Energy Materials Pub Date : 2024-12-31 Epub Date: 2024-08-19 DOI: 10.1080/15384047.2024.2392996

引用次数: 0

Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain. 利用结合受体结合域上不同保守靶点的双特异性抗体拓宽肉瘤病毒的中和作用。

IF 4.1 3区材料科学

ACS Applied Energy Materials Pub Date : 2024-12-31 Epub Date: 2024-08-20 DOI: 10.1080/21645515.2024.2388344

Denise Guerra, Laura Radić, Mitch Brinkkemper, Meliawati Poniman, Lara van der Maas, Jonathan L Torres, Andrew B Ward, Kwinten Sliepen, Janke Schinkel, Rogier W Sanders, Marit J van Gils, Tim Beaumont

{"title":"Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain.","authors":"Denise Guerra, Laura Radić, Mitch Brinkkemper, Meliawati Poniman, Lara van der Maas, Jonathan L Torres, Andrew B Ward, Kwinten Sliepen, Janke Schinkel, Rogier W Sanders, Marit J van Gils, Tim Beaumont","doi":"10.1080/21645515.2024.2388344","DOIUrl":"10.1080/21645515.2024.2388344","url":null,"abstract":"Monoclonal neutralizing antibodies (mAbs) are considered an important prophylactic against SARS-CoV-2 infection in at-risk populations and a strategy to counteract future sarbecovirus-induced disease. However, most mAbs isolated so far neutralize only a few sarbecovirus strains. Therefore, there is a growing interest in bispecific antibodies (bsAbs) which can simultaneously target different spike epitopes and thereby increase neutralizing breadth and prevent viral escape. Here, we generate and characterize a panel of 30 novel broadly reactive bsAbs using an efficient controlled Fab-arm exchange protocol. We specifically combine some of the broadest mAbs described so far, which target conserved epitopes on the receptor binding domain (RBD). Several bsAbs show superior cross-binding and neutralization compared to the parental mAbs and cocktails against sarbecoviruses from diverse clades, including recent SARS-CoV-2 variants. BsAbs which include mAb COVA2-02 are among the most potent and broad combinations. As a result, we study the unknown epitope of COVA2-02 and show that this mAb targets a distinct conserved region at the base of the RBD, which could be of interest when designing next-generation bsAb constructs to contribute to a better pandemic preparedness.","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"20 1","pages":"2388344"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11340772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neutralization potency of the 2023-24 seasonal influenza vaccine against circulating influenza H3N2 strains. 2023-24 年度季节性流感疫苗对流行 H3N2 流感病毒株的中和效力。

IF 4.1 3区材料科学

ACS Applied Energy Materials Pub Date : 2024-12-31 Epub Date: 2024-08-29 DOI: 10.1080/21645515.2024.2380111

Xiande Huang, Ziqi Cheng, Yake Lv, Weixuan Li, Xiaoyu Liu, Weijin Huang, Chenyan Zhao

{"title":"Neutralization potency of the 2023-24 seasonal influenza vaccine against circulating influenza H3N2 strains.","authors":"Xiande Huang, Ziqi Cheng, Yake Lv, Weixuan Li, Xiaoyu Liu, Weijin Huang, Chenyan Zhao","doi":"10.1080/21645515.2024.2380111","DOIUrl":"10.1080/21645515.2024.2380111","url":null,"abstract":"Seasonal influenza is a severe disease that significantly impacts public health, causing millions of infections and hundreds of thousands of deaths each year. Seasonal influenza viruses, particularly the H3N2 subtype, exhibit high antigenic variability, often leading to mismatch between vaccine strains and circulating strains. Therefore, rapidly assessing the alignment between existing seasonal influenza vaccine and circulating strains is crucial for enhancing vaccine efficacy. This study, based on a pseudovirus platform, evaluated the match between current influenza H3N2 vaccine strains and circulating strains through cross-neutralization assays using clinical human immune sera against globally circulating influenza virus strains. The research results show that although mutations are present in the circulating strains, the current H3N2 vaccine strain still imparting effective protection, providing a scientific basis for encouraging influenza vaccination. This research methodology can be sustainably applied for the neutralization potency assessment of subsequent circulating strains, establishing a persistent methodological framework.","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"20 1","pages":"2380111"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing the determinants of influenza and COVID-19 vaccine co-administration decisions in the elderly. 评估老年人联合接种流感疫苗和 COVID-19 疫苗的决定因素。

IF 4.8 3区材料科学

ACS Applied Energy Materials Pub Date : 2024-12-31 Epub Date: 2024-05-13 DOI: 10.1080/21645515.2024.2346966

Seunghyun Lewis Kwon, So-Yeon Kim, Minju Song, Hyung-Min Lee, Seon-Hwa Ban, Mi-Soon Lee, Hyesun Jeong

{"title":"Assessing the determinants of influenza and COVID-19 vaccine co-administration decisions in the elderly.","authors":"Seunghyun Lewis Kwon, So-Yeon Kim, Minju Song, Hyung-Min Lee, Seon-Hwa Ban, Mi-Soon Lee, Hyesun Jeong","doi":"10.1080/21645515.2024.2346966","DOIUrl":"10.1080/21645515.2024.2346966","url":null,"abstract":"This research examines the low rate of co-administration of influenza and COVID-19 vaccines among seniors aged 65 and older in Korea, despite recommendations from authorities and academia worldwide. The study aimed to understand the influence of general characteristics and health beliefs on the vaccination choices of seniors, who were categorized into four groups based on their vaccination status: influenza only, COVID-19 only, both, or neither. A total of 400 participants, aged 65 and above, were selected through proportional stratified random sampling from five major Korean regions for a survey conducted between November 24th and December 15th, 2023. The results indicated no significant differences in general characteristics across these groups. However, regarding the health beliefs showed significant differences in perceived susceptibility and self-efficacy between the influenza-only and co-administration groups. Higher levels of perceived susceptibility and self-efficacy were associated with choosing co-administration. Contrary to previous studies focusing on safety concerns as a primary factor in vaccine hesitancy, this study highlights the role of individual health-related beliefs, particularly perceived susceptibility and self-efficacy, as critical in influencing the decision for co-administration among the elderly in Korea.","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"20 1","pages":"2346966"},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11095571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140917308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

IF 3.6 3区材料科学

ACS Applied Energy Materials Pub Date : 2024-12-31 Epub Date: 2024-05-15 DOI: 10.1080/15384047.2024.2352926

引用次数: 0